Investigational Site Number : 6820001
Riyadh, Saudi Arabia
2 recruiting
Showing 1–2 of 2 trials
Recruiting
Phase 3
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Multiple Sclerosis
Sanofi1,600 enrolled386 locationsNCT06141473
Recruiting
Phase 3
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Multiple Sclerosis
Sanofi900 enrolled338 locationsNCT06141486